newsfilter
← Latest News
GlobeNewswire·

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA for Investigational Treatment of Long-Haul COVID-19

FORT COLLINS, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ:STAB), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced submission to